Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic (Essential) Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic (Essential) Hypertension - Products under Development by Companies 14
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15
Actelion Ltd 15
Bayer AG 16
Chong Kun Dang Pharmaceutical Corp. 17
Daiichi Sankyo Company, Limited 18
Eli Lilly and Company 19
HanAll Biopharma Co., Ltd. 20
Innopharmax Inc. 21
Lee's Pharmaceutical Holdings Limited 22
PhaseBio Pharmaceuticals, Inc. 23
Quantum Genomics SA 24
Takeda Pharmaceutical Company Limited 25
Idiopathic (Essential) Hypertension - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
(amlodipine besylate + candesartan cilexetil) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(atorvastatin calcium + losartan potassium) - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(candesartan cilexetil + nifedipine) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
azilsartan medoxomil - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
carvedilol phosphate CR - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CS-3150 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
lisinopril - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LY-2623091 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
PB-1046 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
PB-1120 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
QGC-001 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
rostafuroxin - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Idiopathic (Essential) Hypertension - Dormant Projects 57
Idiopathic (Essential) Hypertension - Product Development Milestones 59
Featured News & Press Releases 59
Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 59
Jun 12, 2013: Lee's Pharma Enrolls First Patient in Phase IIb Clinical Trial of Rostafuroxin in Italy 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2016 15
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2016 16
Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 17
Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 18
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2016 19
Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 20
Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H2 2016 21
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 22
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 23
Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H2 2016 24
Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Idiopathic (Essential) Hypertension - Dormant Projects, H2 2016 57
Idiopathic (Essential) Hypertension - Dormant Projects (Contd..1), H2 2016 58

List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Top 10 Targets, H2 2016 28
Number of Products by Stage and Top 10 Targets, H2 2016 28
Number of Products by Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Routes of Administration, H2 2016 32
Number of Products by Stage and Routes of Administration, H2 2016 32
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34